News - Page 12 of 13 - Leukaemia Care

11th June 2018

Scottish Medicines Consortium (SMC) recommended the use of inotuzumab ozogamicin

The Scottish Medicines Consortium (SMC) issues restricted recommendation for use of inotuzumab ozogamicin in the treatment of adults with relapsed/refractory acute lymphoblastic leukaemia (ALL) in Scotland.

11th June 2018

Scottish Medicines Consortium (SMC) recommend the use of midostaurin for adult acute myeloid leukaemia patients

Scotland receives a positive recommendation by the SMC for the use of FLT3-mutation-positive targeted therapy midostaurin in first-line AML treatment.

16th May 2018

Ibrutinib for chronic lymphocytic leukaemia (CLL) patients.

Today a letter has been written to the editor at regarding treatment for chronic lymphocytic leukaemia (CLL) patients.

4th May 2018

NICE approves midostaurin for treating Acute Myeloid Leukaemia (AML)

NICE have issued their Final Appraisal Document (FAD) approving the use of midostaurin in first-line treatment of FLT3-mutation-positive acute myeloid leukaemia (AML).

4th May 2018

NICE approves arsenic trioxide for use in acute promyelocytic leukaemia (APL) treatment

NICE have today (Friday 4 May) recommended the use of arsenic trioxide in the treatment of acute promyelocytic leukaemia (APL).

4th May 2018

Brentuximab Vedotin becomes the first drug under the new Cancer Drugs Fund (CDF) to be approved for routine commissioning by the NHS.

Brentuximab vedotin (manufactured by Takeda and also known as Adcetris®) has been available via the Cancer Drugs Fund since 2013. Today it has been approved by NICE (the National Institute for Health and Care Excellence) for routine use within the NHS.

5th February 2018

UK leukaemia patients invited to test new quality of life questionnaire

Leukaemia patients in the UK are being invited to take part in a study that is testing a new questionnaire which aims to support patients and their clinicians

26th January 2018

Health and Technology Appraisals – the importance of patient involvement

Treatments provided by the NHS in England, are often subject to approval for use by NICE and your patient voice and experience is hugely vital within this decision making.

17th January 2018

The ‘Hidden’ Cancer – The need to improve blood cancer care

MPs in parliament are discussing the issues faced by blood cancer patients, in a drive to ensure that cancer policy within the UK is better focussed on the needs of patients.

16th January 2018

#myCNSmatters – what’s been happening?

#myCNSmatters is about raising awareness of the crucial role that Clinical Nurse Specialists (CNSs) play in the care of blood cancer patients, and saying thank you for their hard work